Digoxin Orifarm 62.5 mikrog Norge - norsk - Statens legemiddelverk

digoxin orifarm 62.5 mikrog

orifarm healthcare a/s - digoksin - tablett - 62.5 mikrog

Digoxin Orifarm 250 mikrog Norge - norsk - Statens legemiddelverk

digoxin orifarm 250 mikrog

orifarm healthcare a/s - digoksin - tablett - 250 mikrog

Digoxin DAK 62.5 mikrog Norge - norsk - Statens legemiddelverk

digoxin dak 62.5 mikrog

orifarm as - digoksin - tablett - 62.5 mikrog

Lariam 250 mg Norge - norsk - Statens legemiddelverk

lariam 250 mg

cheplapharm arzneimittel gmbh - meflokinhydroklorid - tablett - 250 mg

Malarone 250 mg / 100 mg Norge - norsk - Statens legemiddelverk

malarone 250 mg / 100 mg

glaxosmithkline as - atovakvon / proguanilhydroklorid - tablett, filmdrasjert - 250 mg / 100 mg

Malarone Junior 62.5 mg / 25 mg Norge - norsk - Statens legemiddelverk

malarone junior 62.5 mg / 25 mg

glaxosmithkline as - atovakvon / proguanilhydroklorid - tablett, filmdrasjert - 62.5 mg / 25 mg

Provaqomyl 250 mg / 100 mg Norge - norsk - Statens legemiddelverk

provaqomyl 250 mg / 100 mg

viatris limited - atovakvon / proguanilhydroklorid - tablett, filmdrasjert - 250 mg / 100 mg

Malarone 250 mg / 100 mg Norge - norsk - Statens legemiddelverk

malarone 250 mg / 100 mg

2care4 aps - atovakvon / proguanilhydroklorid - tablett, filmdrasjert - 250 mg / 100 mg

Clopidogrel Acino Den europeiske union - norsk - EMA (European Medicines Agency)

clopidogrel acino

acino ag - klopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.

Clopidogrel Viatris (previously Clopidogrel Taw Pharma) Den europeiske union - norsk - EMA (European Medicines Agency)

clopidogrel viatris (previously clopidogrel taw pharma)

viatris limited - klopidogrel besilat - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st-segment elevasjon akutte myocardial infarction, i kombinasjon med asa i medisinsk behandlede pasienter kvalifisert for trombolytisk behandling. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. for ytterligere informasjon, vennligst referer til seksjon 5.